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Background: Minucci et al. have proposed in 2010 a rapid, simple and cost-effective HRM method on the
LightCycler 480® apparatus (Roche) for the determination of the 6/6, 6/7 and 7/7 genotypes of the (TA)n
UGT1A1 promoter polymorphism. However, they have not studied the n = 5 and n = 8 alleles which can
be quite frequent in sickle-cell disease patients.
Methods: The aim of our study was to test this HRM protocol to all the 10 possible (TA)n UGT1A1 genotypes
(i.e. 5/5, 5/6, 5/7, 5/8, 6/6, 6/7, 6/8, 7/7, 7/8 and 8/8) by using our SCD cohort of patients.
Results: All genotypes could be unambiguously identiﬁed except 6/7 and 6/8 which give a similar HRM pro-
ﬁle. For those two genotypes, the differentiation necessitates either a direct Sanger sequencing or a second
PCR protocol followed by a 3% agarose gel migration.
Conclusions: For the (TA)n UGT1A1 promoter genotyping of African patients, each lab has to wonder what is
the best way between (i) direct Sanger sequencing of all patients and (ii) HRM protocol for all patients
followed by a complementary analysis to differentiate the 6/7 and 6/8 genotypes.© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license. 1. Introduction
Pigment gallstones are a common clinical complication of sickle-
cell disease (SCD) with a cumulative incidence of about 50% by adult-
hood [1]. This particular susceptibility is explained by the chronic
intra-vascular hemolysis state associated with SCD that often leads
to persistent hyperbilirubinemia. Consequently, in such patients,
reduced expression of the UGT1A1 gene (which encodes the UDP-
glucuronosyltransferase 1A1 enzyme responsible for glucuronidation
of bilirubin into a water-soluble compound) will dramatically en-
hance the risk of cholelithiasis.
The (TA)n tandem repeat sequence within the promoter region is
the main genetic variation that affects the UGT1A1 gene expression.
The wild-type allele is n = 6 (TA) repeats and three other alleles
have been described so far: one with increased transcriptionaloléculaire du Globule Rouge,
pital Edouard Herriot, Place
fax: +33 4 72 11 05 97.
.V. Open access under CC BY-NC-SA licenseactivity (UGT1A1*36 — n = 5) and two leading to a marked reduc-
tion in bilirubin glucuronidation (UGT1A1*28 — n = 7–70% to 80%
reduction; UGT1A1*37 — n = 8 to more than 80% reduction) [2].
The UGT1A1 promoter genotyping is thus frequently used by physi-
cian hematologists to identify SCD patients at particular risk of chole-
lithiasis for which more frequent gallstone echographic researches
would be indicated [3].
Minucci et al. have proposed in 2010 a rapid, simple and cost-
effective HRMmethod for the determination of the 6/6, 6/7 and 7/7 ge-
notypes in Caucasian populations where the n = 5 and n = 8 alleles
are extremely rare [4]. But since these alleles have a frequency of up
to 7%–8% in African patients, a HRMmethod should be able to differen-
tiate up to 10 genotypes (i.e. 5/5, 5/6, 5/7, 5/8, 6/6, 6/7, 6/8, 7/7, 7/8 and
8/8) to be applied for patients of African origin. The goal of this study
was to determine if Minucci's HRM protocol could replace direct Sanger
sequencing for the UGT1A1 promoter genotyping in SCD.
2. Materials and methods — results
2.1. DNA samples and HRM protocol
The Minucci's HRM protocol was repeatedly tested with all ten
possible (TA)n UGT1A1 genotypes in the same experiment. To do so,. 
Fig. 2. Differentiation of the 6/7 and 6/8 genotypes using 3% agarose gel migration. If
the migration is long enough (60 min at 50 V at least), the 6/7 genotype gives a single
band on the gel whereas the 6/8 genotype gives two distinct ones. Ladder: 100 bp.
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notyped by direct Sanger sequencing at the physician's request. On
overall experiments, each UGT1A1 genotype was ‘represented’ by at
least three different patients, except for the 5/5 and 8/8 genotypes
for which we only had one patient in our DNA collection.
TheMinucci's HRMprotocol (including the 70 bp amplicon analyzed)
was exactly reproduced except for the normalizationwindows that were
slightly different: (i) pre-melting: 72–73 °C; (ii) post-melting: 79–80 °C.
For data analysis, we used the ‘Normalized and Temp-shifted Difference’
plot with a 6/7 sample as reference (horizontal line).
2.2. HRM results
An example of the obtained plot is given in Fig. 1. All genotypes are
clearly distinguishable except the 6/7 and 6/8 genotypes. Despite many
other set of parameters (temperature shift, normalizationwindows, ge-
notype chosen as reference, etc.) were tried, these two genotypes could
not be differentiated at all in a robust and reproducible way.
2.3. Differentiation of 6/7 and 6/8 genotypes by 3% agarose gel migration
This differentiation did not appear possible with the 70 bp PCR
product used in the HRM protocol: for both genotypes, a single band
was obtained on the gel whatever the voltage used and the duration
of migration (data not shown). Since we wondered if the 4 bp differ-
ence between TA = 6 and TA = 8 alleles could give rise to two distinct
bandswith a longer PCR fragment, we also tried a 3% agarose gelmigra-
tion with the PCR products obtained in our classical UGT1A1 Sanger se-
quencing protocol (250 bp; forward: 5′-CCCTGCTACCTTTGTGGACT-3′;
reverse: 5′-CCATCCACTGGATCAACA-3′). Very interestingly, the 6/7
and 6/8 genotypes could then be distinguishable provided that the mi-
gration was long enough (60 min at 50 V at least): the 6/7 genotype
gives a single band on the gel whereas the 6/8 genotype gives two dis-
tinct ones (Fig. 2).
3. Discussion
Our work is the direct complement of Minucci's one as it focuses on
all possible (TA)n UGT1A1 promoter genotypes and not only the most
frequent ones. When considering the possible allelic combinations, it
appears that they all can be distinguished from each other by theFig. 1. Normalized and temperature shifted difference plots for the UGT1A1(TA)n polymorph
each other, except the 6/7 and 6/8 genotypes.previously published HRM protocol, except the 6/7 and 6/8 genotypes
which give exactly the same proﬁle. This is not inconvenient in Cauca-
sian populations where the n = 8 allele is extremely rare. However, it
appears problematic in African populations where the n = 8 allele is
potentially muchmore frequent, SCD populations being a typical exam-
ple. For such patients, in front of a ‘6/7 or 6/8’HRM proﬁle, the differen-
tial diagnosis has to be done, either by direct Sanger sequencing or by
our proposed secondary PCR reaction followed by a 3% agarose gel
migration.
Consequently, the question of the most efﬁcient strategy should
really be asked when considering that about 40% of SCD patients have
a 6/7 genotype (personal data on our SCD cohort). Indeed, when a com-
plementary experiment is required, the main advantages of HRM in
comparison to direct sequencing (lower workforce, time saving tech-
nique and lower costs) become much less obvious. So, for laboratories
performing the (TA)n UGT1A1 genotyping on SCD patients, what is the
best way between (i) direct sequencing of all patients and (ii) an
HRM protocol followed by a complementary analysis for about 40% of
them? The answer is not evident but greatly depends on each lab's
organization and equipments. Provided that the two methodologies
are technically possible and well-controlled, direct sequencing seems
more advisable for small series (less than 10 patients) because up to
20 control samples (10 possible genotypes in duplicates) should ideally
be included in each HRM protocol but, for larger series, the HRM proto-
col becomes more and more cost-efﬁcient.ism genotyping. All the 8 possible (TA)n combinations are clearly distinguishable from
260 V. Thomas et al. / Clinica Chimica Acta 424 (2013) 258–260In conclusion, our work illustrates two general considerations that
should always be taken into account when an HRM protocol is used
not for screening but for the search of a particular mutation or single
nucleotide polymorphism [5,6]: (i) all alleles must have been tested
during the development process and (ii) two alleles can remain
undistinguishable by HRM whatever the parameters used. As to the
UGT1A1 genotyping, other polymorphisms than the (TA)n repeat
can also be determined by a HRM method [7,8].References
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